Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05143684 |
Other study ID # |
LUD-CS |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
June 1, 2020 |
Est. completion date |
July 31, 2020 |
Study information
Verified date |
November 2021 |
Source |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Background: Left uterine displacement (LUD) has been questioned as an effective strategy to
prevent aortocaval compression after spinal anesthesia (SA) for cesarean delivery (CD). The
investigators tested if LUD has a significant impact on cardiac output (CO) in patients
undergoing CD under SA during continuous non-invasive hemodynamic monitoring.
Methods: Forty-six patients were included in the final analysis. The investigators considered
4 timepoints of 5 minutes each: T1=baseline with LUD; T2=baseline without LUD; T3=after SA
with LUD; T4=after SA without LUD. LUD was then repositioned for CD. Primary outcome was to
test if CO decreased from T3 to T4. We also compared CO between T1 and T2 and other
hemodynamic variables: mean, systolic and diastolic blood pressure (respectively MAP, SAP and
DAP), heart rate (HR), stroke volume (SV), stroke volume variation (SVV), pulse pressure
variation (PPV), contractility (dP/dt), dynamic arterial elastance (Eadyn) at the different
timepoints. Data on fetal Apgar scores and umbilical arterial and venous pH were collecte
Description:
The primary outcome was to test if CO decreases significantly after LUD removal in patients
under SA for CD. This is a prospective observational study.
Data were gathered from pregnant patients who, in addition to standard monitoring, underwent
perioperative non-invasive hemodynamic monitoring by ClearSight system on the Edwards
Lifesciences HemoSphere platform (Edwards Lifesciences, Irvine, CA).
The parameters were recorded at 20 seconds-intervals. The investigators considered 4
timepoints. T1 were the baseline values recorded for 5 minutes, after initial stabilization
of parameters, with the patient laying down on the operating table with LUD. At T2, LUD was
removed and we considered for the analysis hemodynamic data of the subsequent 5 minutes. The
investigators indicated as T3 the 5 minutes following SA with a satisfactory sensory block
and as T4 the subsequent 5 minutes following LUD removal. Figure 1 summarizes the timepoints
of our analysis. LUD was accomplished by positioning a wooden wedge wrapped with cotton, to
make it comfortable, and medical sheets with a measured angle of 15° under the right flank of
the laying down patient. In all patients, after T4 the 15° wooden wedge was positioned again
and surgery was performed with LUD.
Anesthesia was standard spinal procedure, fluid management was left to the attending
anesthesiologist.
The attending anesthesiologist was blinded to the advanced hemodynamic parameters from the
ClearSight system except for the continuous BP values. The investigators defined hypotension
as an absolute value of MAP < 65 mmHg. This value was considered as trigger for the attending
anesthesiologist for the administration of norepinephrine 5 mcg. Norepinephrine boluses were
repeated to reach a MAP>65mmHg. Bradycardia was defined as a heart rate of < 60 bpm. Atropine
0.5 mg was administered for the treatment of bradycardia combined with hypotension, or for an
absolute value of heart rate < 45 bpm. After delivery, Oxytocin was administered to
facilitate the uterine contraction.
We also evaluated the impact of maternal blood pressure and CO on fetal outcome collecting
neonatal Apgar scores at 1 and 5 minutes after birth, and umbilical cord arterial and venous
pH.